CC-90003, a covalent ERK1/2 inhibitor, disrupts signaling pathways and impacts cell growth and survival, particularly in KRAS-mutant cells (Aronchik et al., 2019), indicating its therapeutic potential in colorectal cancer. This evidence concerns the gene MAPK3 and colorectal cancer.